197,000 UK lives saved thanks to breast cancer advances
Almost 200,000 UK deaths from breast cancer have been averted since the late 80s, according to a new report.
Experts said that changes in how cancer is detected, diagnosed and treated have 'all been essential to these improvements'.
Overall, 1.5 million cancer deaths in the UK have been prevented since 1989, according to a new study predicting European cancer deaths in 2025.
But there will still be 173,300 cancer deaths overall in the UK this year, academics said.
Most cancer deaths among men in the UK in 2025 will be due to bowel; lung and prostate cancers.
While most cancer deaths among UK women will be due to bowel; lung and breast cancers.
Breast cancer deaths in the UK in 2025 will be lower than those observed in 2020 – with 11,400 women expected to die from breast cancer this year compared to 11,547 deaths in 2020.
The UK is also estimated to buck the trend when it comes to breast cancer deaths among elderly women – with deaths among over 80s attributed to breast cancer expected to rise in many European countries but fall in the UK.
Carlo La Vecchia, professor of medical statistics and epidemiology at the University of Milan in Italy, said: 'Elderly women are not covered by screening and probably are less favourably affected by the substantial advances in breast cancer management, including improvements in chemo and hormone therapy, but also in radiotherapy and surgery.
'The increased prevalence of overweight and obesity over the last few decades in most of northern and central Europe has led to an increased risk of breast cancer.
'In the elderly, this has not been counter-balanced by improved diagnosis and management. This accounts for the increased mortality in people aged 80 and over.'
In England, all women aged 50 to 71 are invited for breast cancer screening every three years.
Prof La Vecchia added: 'We estimate that between 1989 and 2025, 373,000 breast cancer deaths have been avoided in the EU and 197,000 in the UK.
'Most of these are due to improved management and therapy, but 25-30% are likely to be attributable to more widespread screening and early diagnosis.
'Given that breast cancer is now a largely curable cancer that requires modern integrated approaches, it is essential that all diagnoses of breast cancer are referred to comprehensive cancer centres, which can offer the complete range of therapies that might be required.
'As indicated by the unfavourable trends in elderly women, control of overweight and obesity is a priority now, not only for cardiovascular diseases, but also for cancer, including breast cancer.'
Commenting, Jon Shelton, Cancer Research UK's head of cancer intelligence, said: 'Breast cancer mortality rates have fallen substantially in the UK since the early 1970s, and it's extremely positive to see that trend continue.
'Breakthroughs in how we detect, diagnose and treat the disease have all been essential to these improvements.
'Studies like this showcase the power of science, and if the UK Government's upcoming national cancer plan for England prioritises reform and investment in cancer services and getting research and innovation into care, we'll see even more improvements for people affected by cancer.'
Dr Kotryna Temcinaite, head of research communications and engagement at Breast Cancer Now, said: 'It's reassuring that this research suggests that nearly 197,000 deaths from breast cancer have been avoided in the UK in the last 37 years across women of all ages.
'This could be due to a combination of increased awareness and improvements in cancer detection and treatment. But the stark reality is that 11,500 women still die from this devastating disease each year in the UK, making research into how we better diagnose and treat breast cancer more needed than ever.
'Most breast cancers (80%) occur in women aged over 50, and a quarter (25%) of cases are diagnosed in women aged 75 and over.
'It's crucial that all women regularly check their breasts and get to know their 'normal'.'
Dame Cally Palmer, national cancer director at NHS England, said: 'It's incredibly encouraging that deaths from breast cancer in the UK are continuing to fall as a result of improved early diagnosis and treatment.
'We know a third of women don't take up their invites for the scans which can detect cancer earlier, when treatment has the best chance of success – so I'd urge anyone who receives an invite to book a potentially life-saving appointment for NHS breast cancer screening.'
The new review, by a team of international researchers, also predicts small reductions in lung cancer deaths for both men and women in the UK.
But bowel cancer deaths are expected to increase from the absolute numbers in 2020, according to the new study, which has been published in the journal Annals of Oncology.
Pancreatic cancer deaths are also expected to rise, according to the estimates.
Prof La Vecchia said: 'Trends in cancer mortality continue to be favourable across Europe, however, there are a few negative indications – these include deaths from bowel cancer in people younger than 50, which have started to increase in the UK and several central and northern Europe countries, mainly due to increased prevalence of overweight and obesity in the young who are not covered by colorectal cancer screening.
'In addition, death rates from pancreatic cancer are not decreasing in the EU, and it is now the fourth cause of cancer death in Europe after lung, colorectal and breast cancer.
'Death rates from lung cancer are starting to level off but not yet to decrease in EU women. The trends in pancreatic and female lung cancer underline the urgency of implementing stricter tobacco control across Europe.'

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
SpliceBio lands $135M for a new kind of eye gene therapy
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. SpliceBio, a Spanish biotechnology company working on next-generation gene therapies, said Wednesday it raised $135 million in a Series B round to advance its lead program in Stargardt disease into further clinical testing. The startup is built around a technology that's meant to overcome a key limitation of current gene therapies. Scores of gene therapy developers use adeno-associated viruses, or AAVs, to deliver genetic cargo into the body. But because of their small size, AAVs can't carry larger corrective genes, leaving many diseases out of reach or forcing companies to come up with creative solutions. One example is in Duchenne muscular dystrophy. Because of the large size of the gene coding for the muscle-protecting protein dystrophin Duchenne patients lack, several companies, like Sarepta Therapeutics, have developed gene therapies that make a shortened form. The approach comes with drawbacks, however, as a truncated version of the protein might not work as well as the original. SpliceBio has a different workaround. The company is using two separate AAVs to send pieces of a large gene into cells. Once inside, specially engineered splicing molecules help reassemble their cargo into full-length proteins. Stargardt disease, for example, is caused by mutations to the ABCA4 gene, which is too large to stuff into an AAV. SpliceBio says its method can help the body produce a functional version of the protein that gene produces. Its lead program, SB-007, is in a Phase 1/2 trial. SpliceBio isn't the only biotech pursuing this type of approach to treat Stargardt, an inherited eye condition that causes progressive vision loss. Another European company, AAVantgarde, has a similar type of program in early-stage testing. SpliceBio's technology is based on research conducted at Princeton University, where co-founder and CEO Miquel Vila-Perelló was studying protein design and engineering. Launched in 2014 under the name ProteoDesign, the biotech is also working on additional programs in ophthalmology, neurology and other undisclosed therapeutic areas. Its Series B round was co-led by EQT Life Sciences and Sanofi Ventures, and involved seven other backers including Roche Venture Fund, New Enterprise Associates and Novartis Venture Fund. "The support from such high-quality investors underscores the strength of our programs and our unique protein splicing platform and its potential to unlock gene therapies for diseases that remain untreatable today,' Vila-Perelló said in a statement. The company raised €50 million in a Series A round in 2022. Gene and cell therapy startups backed by the roughly two dozen investment firms BioPharma Dive tracks have secured a little over $1.1 billion in venture dollars so far in 2025. Half of those fundings have come in the form of 'megarounds' exceeding $100 million apiece, continuing an ongoing trend. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
Pfizer CEO Mentioned No Drug Price Commitments by Pfizer Inc. (PFE)
Pfizer Inc. (NYSE:PFE) is one of the best wide moat stocks to buy now. On June 9, Pfizer, along with other drug manufacturers, had a meeting with the Trump administration to talk about reducing US drug prices. However, Pfizer's chief executive, Albert Bourla, mentioned that no commitments have been agreed upon. President Trump ordered drugmakers last month to slash the prices of their medicines so they match what other countries are paying. As per this executive order, the government was to select 'Most Favored Nation' target prices in 30 days. The Department of Health and Human Services called for drugmakers in the United States to revise their prices to align with the lowest price paid by similar high-income countries. At the Goldman Sachs Global Healthcare Conference, Albert Bourla commented: 'I don't know what we will hear in 30 days,' Reiterating Pfizer's focus on high-level ideas, Bourla added: 'The administration already started series of meetings with companies. … The meetings were cordial, but they were not digging into the substance,' A medical technician wearing protective gloves and a mask mixing a biopharmaceutical solution. For now, it is unclear how the US government will bring down drug prices, and this policy will be hard to execute, as per analysts and legal professionals. A spokesperson commented that Health Secretary Robert F. Kennedy, Jr. would launch a system where American patients can directly buy their medicine from drug makers that sell to Americans at a 'Most-Favored-Nation' price. Pfizer's Bourla was hopeful that, due to American pressure on European nations to pay higher prices, the overall drug prices could rise. He stated that if America starts controlling prices, Pfizer Inc. (NYSE:PFE) could withhold drugs for government reimbursement in some countries if they do not increase prices there. He clarified: 'I don't think we will remove our products from the markets there – we will just remove them from reimbursement. We will leave them in open market.' Pfizer manufactures and sells biopharmaceutical products worldwide, catering to heart health, infectious diseases, migraines, immune disorders, and cancer. While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
8 hours ago
- Yahoo
FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL STUDYING BOTANICAL PSILOCYBIN FOR PROLONGED GRIEF DISORDER
The clinical trial at Linkoping University will study Filament's botanical psilocybin drug candidate, PEX010 VANCOUVER, BC, June 11, 2025 /CNW/ - Filament Health Corp. (OTC: FLHLF) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced that the Swedish Ethical Review Authority and the Swedish Medical Products Agency have authorized a double-blind phase 2 clinical trial studying its botanical psilocybin drug candidate, PEX010, at Linkoping University. The trial will be the first to study the effects of psilocybin in the treatment of prolonged grief disorder. "In an aging society where people may outlive their family members by decades, it is crucial to develop treatment options for those with prolonged grief disorder," said Dr. Rebecca Böhme, Associate Professor at the Linkoping Center for Social and Affective Neuroscience. "This trial will assess whether psilocybin can improve adaptation to the loss experience. We are grateful to Filament Health for facilitating this research." People with prolonged grief disorder are at a 20 percent increased mortality risk. Previous psychological research suggests that the loss of a close person affects self-identity, an aspect of the higher cognitive self. Psilocybin is suggested to cause a transient shift from reliance on prior experiences towards current sensations. The clinical trial at Linkoping University will utilize this shift combined with a self-touch intervention to support re-learning about the bodily self in a trial population of 120 individuals. "We're pleased to provide PEX010 to Linkoping University for this much-needed area of research," said Benjamin Lightburn, Co-Founder and Chief Executive Officer at Filament Health. "This will be the ninth European clinical trial to study our drug candidate, positioning Filament as the region's leading supplier of GMP psilocybin." The trial at Linkoping University is expected to begin dosing in Q3 2025. PEX010 is authorized for investigation in 52 clinical trials worldwide for 14 mental health indications. ABOUT FILAMENT HEALTH (OTC:FLHLF)Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates. Learn more at and on Twitter, Instagram, and LinkedIn. FORWARD LOOKING INFORMATIONCertain statements and information contained in this press release and the documents referred to herein may constitute "forward‐looking statements" and "forward‐looking information," respectively, under Canadian securities legislation. Generally, forward‐looking information can be identified by the use of forward‐looking terminology such as, "expect", "anticipate", "continue", "estimate", "may", "will", "should", "believe", "intends", "forecast", "plans", "guidance" and similar expressions are intended to identify forward‐looking statements or information. The forward‐looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward‐looking statements. Forward‐looking statements regarding the Company are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward‐looking statements or forward‐looking information, including the timing and results of clinical trials, the ability of the parties to receive, in a timely manner and on satisfactory terms, the necessary regulatory, court and shareholders approvals; the ability of the parties to satisfy, in a timely manner, the other conditions to the completion of the proposed business combination; other expectations and assumptions concerning the transactions contemplated in the proposed business combination; the available funds of the parties and the anticipated use of such funds; the availability of financing opportunities; legal and regulatory risks inherent in the psychedelic drug development industry; risks associated with economic conditions, dependence on management and currency risk; risks relating to U.S. regulatory landscape; risks relating to anti-money laundering laws and regulation; other governmental and environmental regulation; public opinion and perception of the psychedelic drug development industry; risks related to the economy generally; risk of litigation; conflicts of interest; risks relating to certain remedies being limited and the difficulty of enforcement of judgments and effect service outside of Canada; and risks related to future acquisitions or dispositions. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward‐ looking statements and forward‐looking information. Filament will not update any forward‐looking statements or forward‐looking information that are incorporated by reference herein, except as required by applicable securities laws. SOURCE Filament Health Corp. View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data